The results showed a higher proportion of HR-positive patients with HER2 low-expression breast cancer (approximately 89.6%) and a lower proportion of histological grade III cases in comparison with patients with HER2-0 breast cancer. This evidence concerns the gene ERBB2 and breast cancer.